Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
https://www.anavex.com/post/anavex-life-sciences-announces-grant-of-u-s-patent-covering-blarcamesine-anavex-2-73-for-treatmen
Forgot how to modify a post. If someone can embed my last you tube post from Neurology about Anavex… greatly appreciated
“Leading Somebody Is Like Serving Somebody" Chairman, Co-Founder Partex NV
https://www.businessworld.in/article/-Leading-Somebody-Is-Like-Serving-Somebody-Chairman-Co-founder-Partex-NV/06-12-2022-456948
“FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer’s Drug”
https://www.wsj.com/articles/biogen-aduhelm-fda-approval-congressional-investigation-11672333482
Second death linked to potential antibody treatment for Alzheimer’s disease
Woman’s brain hemorrhage while receiving Eisai’s widely heralded lecanemab heightens concerns overs its safety
27 NOV 2022 8:00 PM
BY
CHARLES PILLER
https://www.science.org/content/article/second-death-linked-potential-antibody-treatment-alzheimer-s-disease
Something also to keep an eye on this week.
Institutional holdings reporting
https://fintel.io/so/us/avxl
Today 11/14/22 11:20AM EST
Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the Guggenheim 4th Annual Immunology and Neurology Conference 2022 on Monday, November 14, 2022, at 11:20 AM ET, to be held at the St. Regis Hotel in New York, NY.
A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. An archived edition of the session will be available later that day.
https://www.anavex.com/post/anavex-life-sciences-to-present-at-the-guggenheim-4th-annual-immunology-and-neurology-conference
Will they “pitch around” the current batter (A2-73) and go after the on deck hitter (A3-71)? Get your popcorn ready…7th inning stretch time.
From
Aug 2
Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022
ANAVEX®3-71 effect is supported by biomarkers: Decrease of extracellular Ab (Abeta) deposition and reduced pathological inflammatory glial cell recruitment towards hippocampal neurons (p ≤ 0.01)
“These results strengthen our SIGMAR1 product platform and validate Anavex’s approach to CNS target selection and drug discovery,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “This data increases Anavex’ confidence in the potential of our Precision Medicine technology to address serious neurodegenerative diseases.”
https://www.anavex.com/post/anavex-announces-long-lasting-effect-of-anavex-3-71-preventing-cognitive-decline-in-a-transgenic-rat
Oncology highlighted but I believe pertains to the work the TGD and the Anavex team are doing.
“Connecting Health Systems and Life Science Researchers To Maximize the Potential of Real-world Evidence.
There needs to be a bigger emphasis and move towards connecting the life science companies who are doing the work of using biomarkers to develop therapies with the health systems where a majority of cancer care in the US actually occurs. Not enough patients are getting the benefit of precision medicine today. It starts with data sharing and real world evidence.”
By ANNA BERRY
https://medcitynews.com/2022/11/biomarkers-drug-development-precision-medicine-cancer-treatment/
31 October 2022
Dementia praecox revisited: FT dementia and schizophrenia
https://insightplus.mja.com.au/2022/42/dementia-praecox-revisited-frontotemporal-dementia-and-schizophrenia/
“Advancing Real-World Evidence Program”
https://www.fda.gov/drugs/development-resources/advancing-real-world-evidence-program
29 September 2022
Alzheimer’s drug slows mental decline in trial — but is it a breakthrough?
https://www.nature.com/articles/d41586-022-03081-0
— George Perry (@geoperry) September 30, 2022
Yes Nidan thanks to you and others. Really enjoy your posts. Keep them coming.
Patience and Perspective
“WHY WE FAIL TO TREAT NEURODEGENERATIVE DISEASES”
https://tmrwedition.com/2022/08/16/why-we-fail-to-treat-neurodegenerative-diseases/
— George Perry (@geoperry) August 16, 2022
“We need to make it all real....connect all the dots.”
I guess we will know how and why TGD (and Anavex team) did what they did….eventually. Come on Dr M show us the “Iceberg”!
Ok..now back to… Patience and Perspective
Understood, just merely pointing out the “Big Money” game.
Bill Gates still in the game.
“Bill Gates Is Reupping His Commitment To Alzheimer’s Research And Detection”
https://www.forbes.com/sites/kerryadolan/2022/07/30/bill-gates-is-reupping-his-commitment-to-alzheimers-research-and-detection/?sh=6fcb42936a83
All good. I wasn’t 100% sure myself. It’s hard waiting on “new” news or any updated progress. I wish the patients and their caregivers could shout from the rooftops “Anavex Now!”
Patience and Perspective
I believe that is from AD/PD 2022 (march2022) we are waiting on AAIC poster.
https://aaic.alz.org/overview.asp
Expert delivers analysis of fabricated Alzheimer’s research
https://www.newsnationnow.com/science/expert-delivers-analysis-of-fabricated-alzheimers-research/
— George Perry (@geoperry) July 28, 2022
Ha ha yes..I put up prayer hands…emoji and it came up question marks. Yes keep the FAITH!
Great post Tred! Keep the faith ??
Patience and Perspective
Yes and hopefully 2-73 for extra help if need be.
New Research from Top Sleep Scientists Reveals 7 out of 10 Americans Need Better Sleep; Not 3 in 10 as Commonly Reported
https://www.prnewswire.com/news-releases/new-research-from-top-sleep-scientists-reveals-7-out-of-10-americans-need-better-sleep-not-3-in-10-as-commonly-reported-301590732.html
“Hundreds of billions of dollars in potential sales would be on tap for whoever designs a working therapy that can slow or stop the progression of these diseases.”
Does anyone else remember the number 67+ Billion $ being floated awhile back? TGD said something to the effect of “We are going for more than that”. It seems it could be potentially higher. Maybe someone can find the link to that 67 Billion #
FDA Releases Action Plan for Rare Neurodegenerative Diseases, Including ALS
Five-Year Plan Fulfills a Requirement of the Accelerating Access to Critical Therapies for ALS Act
https://www.fda.gov/news-events/press-announcements/fda-releases-action-plan-rare-neurodegenerative-diseases-including-als?utm_medium=email&utm_source=govdelivery
From Jan 10:
https://www.anavex.com/post/anavex-life-sciences-reports-positive-results-from-phase-1-clinical-trial-of-anavex-3-71
Great post Pete. Thank you (from a fellow LONG time Long)
Interesting and thought provoking twitter thread (AD)
Scientists Question Data Behind an Experimental Alzheimer’s Drug: Studies linked to @CassavaSciences, once a stock market favorite, have been retracted or challenged by medical journals.https://t.co/bOQ4R3vUGh via @apoorva_nyc @Adrian_H
— Ash Paul (@pash22) April 19, 2022
Scientists Question Data Behind an Experimental Alzheimer’s Drug
Studies linked to Cassava Sciences, once a stock market favorite, have been retracted or challenged by medical journals.
https://www.nytimes.com/2022/04/18/health/alzheimers-cassava-simufilam.html
“The 14 largest pharmaceutical companies by market cap, including Pfizer Inc. and Johnson & Johnson, face the loss of tens of billions of dollars in revenue over the next decade from patent expirations on branded drugs, and have a com-bined $650.5 billion in capacity to do deals this year, according to Ronny Gal, a Bernstein & Co. analyst.”
“The big pharma companies all have big holes in their pipelines and are looking to fill them” with acquisitions, said Mr. Gal. “When pharma begins to pull the trigger, you should see the biotechs begin to turn” upward again.
https://www.wsj.com/articles/biotech-stocks-once-booming-enter-bear-territory-11648990980
WEDNESDAY, APRIL 27
2:00 pm
• A Psychometric Evaluation of the Rett Syndrome Behaviour Questionnaire in children and adults – Walter Kaufmann, MD (Anavex Life Sciences Corp.)
https://www.rettsyndrome.org/wp-content/uploads/IRSF_Scientific-Meeting-Agenda_3.16.22-1.pdf
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access
NEW YORK – September 27, 2021
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will join a panel discussion titled, “Fragile X Syndrome Case Study: From Preclinical to Clinical, Making Drug Development Efficient through Community-based Collaboration” at the 5th Pharma Pricing, Reimbursement & Market Access 2021 conference on Wednesday, September 29th at 2:40 pm EDT.
This Conference will provide an overview of global pricing, market access systems and cost management techniques, as well as in-depth discussion of some of the most current trends and changes. This Conference will bring together top pharmaceutical, biotechnology, and regulatory representatives under one roof that will address the key issues of the industry. It will be studied with the help of case studies and industry experiences. The virtual event is held September 28th - 29th, 2021.
https://www.anavex.com/post/anavex-life-sciences-announces-participation-at-5th-pharma-pricing-reimbursement-market-access
Walter Kaufmann starting at 54:00 (Randi Hagerman 0:00 -- 54:00)
" rel="nofollow" target="_blank">https://www.youtube.com/watch?v=
There is always Tuesday Just wanted to say appreciate all your contributions to the board. GLTA